Harnessing Host Defense Responses To Fight Cancer

Manhattan BioSolutions is an emerging biotech company focused on the discovery of novel precision biologics that harness the power of microbial recognition and host-defense pathways for the treatment of advanced, metastatic cancers. We develop innovative tumor-targeted agents that selectively destroy cancer cells while sparing healthy tissues

Scientific Platforms

Degrader Nucleases

Developing a new generation of human nuclease therapeutics with potent anti-cancer activities. The RNA degrador platform utilizes engineered derivative of naturally occurring enzyme involved in host defense to selectively degrade RNA in tumors



Developing novel biologics, Antibody-Drug Conjugates (ADCs) that target cell-surface receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated or direct anti-tumor mechanisms

In the News
Contact Us
For business development or general inquiries, please fill out a contact form. If you’re an accredited investor, please contact us at ir @ manhattanbiosolutions.com

Center Avenue, Fort Lee
New Jersey, NY 07024

80 5th Avenue, 1002
New York, NY 10011